Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome

Trial Profile

Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tivanisiran (Primary)
  • Indications Dry eyes
  • Focus Registrational; Therapeutic Use
  • Sponsors PharmaMar; Sylentis
  • Most Recent Events

    • 16 Feb 2024 Status changed from recruiting to completed.
    • 09 Feb 2024 Primary endpoint (Change from baseline in Dry Eye Symptom score) has not been met.
    • 09 Feb 2024 Results published in the Sylentis Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top